Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Outlook Therapeutics has highlighted its newly appointed Chief Financial Officer, Kevin Lundquist, in a Virtual Investor segment. The company is preparing for the U.S. commercial launch of its FDA-approved drug, LYTENAVA, for treating wet age-related macular degeneration (AMD).
Outlook Therapeutics appointed Kevin Lundquist as chief financial officer as it shifts to a commercial-stage launch of LYTENAVA.